Lisinopril-Induced Liver Injury: An Unusual Presentation and Literature Review

Al-Rifaie, Ammar and Khan, Mir Azam and Ali, Amjad and Kumari Dube, Asha and Gleeson, Dermot and Hoeroldt, Barbara (2020) Lisinopril-Induced Liver Injury: An Unusual Presentation and Literature Review. European Journal of Case Reports in Internal Medicine, 7 (7). pp. 1-4. ISSN ISSN: 2284-2594

[img]
Preview
Text
1600-Article Text-12698-1-10-20200414.pdf - Published Version

Download (359kB) | Preview
Official URL: https://www.ejcrim.com/index.php/EJCRIM/issue/view...

Abstract

Lisinopril is an angiotensin converting enzyme inhibitor (ACE-I) that has been on market for more than 25 years. ACE-I are usually well tolerated and rarely have serious or life-threatening side effects. We describe an unusual presentation of fulminant hepatic cholestasis probably secondary to lisinopril. To our knowledge, this is the second case report which shows lisinopril-induced liver injury though a cholestatic mechanism. The patient was a 59-year-old woman with type 2 diabetes, a high body mass index and hypertension, who presented with a 5-week history of jaundice and itching. She had been started on lisinopril for diabetic nephropathy 8 weeks before admission. Other causes for cholestasis had been excluded through non-invasive immunology and virology screening, an ultrasound of the liver, magnetic resonance cholangiopancreatography and a liver biopsy. The biopsy was consistent with drug-induced liver injury. Lisinopril was stopped 2 weeks before admission. The patient’s hospital stay was complicated by contrast nephropathy and influenza A which were both treated appropriately. Unfortunately, the liver cholestasis did not completely resolve following withdrawal of lisinopril and the patient died after 4 months. A literature search yielded only six other reported cases of lisinopril-induced liver injury. Five cases described hepatocellular damage and one showed cholestatic injury.

Item Type: Article
Uncontrolled Keywords: Angiotensin converting enzyme inhibitors, lisinopril, drug-induced liver injury, cholestasis
Subjects: 600 Tecnologia - Scienze applicate
600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici)
600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 616 Malattie (classificare qui la Clinica medica, la medicina basata sull'evidenza, la Medicina interna, la Medicina sperimentale)
Depositing User: Marina Spanti
Date Deposited: 14 Dec 2021 14:33
Last Modified: 14 Dec 2021 14:33
URI: http://eprints.bice.rm.cnr.it/id/eprint/20925

Actions (login required)

View Item View Item